Stelis Biopharma, a vertically integrated biopharma and vaccines company and the biotech arm of Strides Pharma Science Limited, has appointed Mark W. Womack as the new CEO. He is also the managing director designate and will be inducted to the board later subject to necessary statutory clearances and processes.   As the new CEO and managing director, Womack will provide leadership to drive an aggressive growth and profitability strategy for Stelis in its business streams that include global cont...